Nvidia Tops Microsoft as World’s Most Valuable Companyby Mark Eisenberg 19.06.2024Nvidia surpasses Microsoft to become world's most valuable company, driven by AI boom; dominates Wall Street trading and market value.
Bitcoin Price Predictions: Can Halving Propel It to $50K or $100K?by John Darbie 18.06.2024Bitcoin's past halvings signal bull markets and potential peaks of $110K-$140K during the current cycle. Track key levels and stay ...
PTOUNX Exchange: Pioneering the Future of Financeby John Darbie 18.06.2024Discover how PTOUNX Exchange leads the cryptocurrency future with AI-driven features, enhanced security, and strict legal compliance.
Ethereum Price Prediction: Will ETH Plunge to $3.2K?by John Darbie 18.06.2024ETH struggles to regain $3,500 amid bearish sentiment. Will it drop to $3.2K? Current trading volumes suggest increased market volatility.
Autodesk’s Blum Sells $3.9M in Shares Amid Market Movementsby Mark Eisenberg 18.06.2024Autodesk COO Steven Blum sells shares worth over $3.9M as part of a trading plan; retains 54,136 shares; Autodesk reports ...
Bitcoin Rallies to $67K, XRP Leads Altcoin Surgeby John Darbie 18.06.2024Bitcoin bounces back to $67K after volatile week; XRP leads altcoin recovery with 5% gain. Bitcoin miners and traditional markets ...
Ethereum Set to Surge 50% Amid BTC Rivalry & ETF Approvalby John Darbie 18.06.2024Ethereum could surge 50% vs. Bitcoin in 2023, driven by the inverse head-and-shoulders pattern and Spot Ethereum ETF approvals. Stay ...
Ethereum ETFs Anticipated in July: ETH Price to Hit $6,000?by John Darbie 18.06.2024Ethereum ETFs may launch by July 2, per Bloomberg analyst Eric Balchunas; SEC groundwork nearly done, ETH price could reach ...
XRP Price Surge: Why XRP Outperforms Bitcoin’s Struggleby John Darbie 17.06.2024XRP's price fluctuates near $0.5; increased whale activity and market volatility highlight potential movements. Bitcoin steadies above $65,000.
Roche’s Hemlibra Battles Fierce Competition Amid Rating Holdby Mark Eisenberg 17.06.2024Roche's Hemlibra braces for fierce competition from Novo Nordisk's mim8, as analysts give mixed ratings and forecasts on Roche's strategic ...